Previous Close | 5.98 |
Open | 5.95 |
Bid | 0.00 x 1100 |
Ask | 0.00 x 1100 |
Day's Range | 5.95 - 6.70 |
52 Week Range | 4.86 - 24.54 |
Volume | |
Avg. Volume | 101,580 |
Market Cap | 254.663M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.76 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for THRX
HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ: THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. The analysts believe THE-630 can adequately tackle resistance in GIST by using dynamic molecular touchpoints that aim to ensure retention of inhibition. Related
Rubric Capital disclosed a large stake in Mereo BioPharm. Foresite Capital raised its stake in Theseus Pharmaceuticals.
We can readily understand why investors are attracted to unprofitable companies. For example, although...